Assessment of Composite Inflammatory Ratios in Juvenile Idiopathic Arthritis and Their Association With Disease Activity
- Sponsor
- Sohag University
- Study ID
- NCT07083466
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 16 Years
- Healthy Volunteers
- Accepted
Interventions
- complete blood count — DIAGNOSTIC_TESTblood test
- serum albumin — DIAGNOSTIC_TESTblood test
Study Details
Juvenile Idiopathic Arthritis (JIA) is a prevalent pediatric rheumatic disorder characterized by persistent inflammation of one or more joints in children and adolescents. This chronic condition is a major contributor to both short- and long-term morbidity and functional disability We aim in this study to investigate the role of CAR, PLR, NLR ,systemic inflammatory index (SII ) and NAR ( SII and NAR have never been evaluated before in JIA patients ) as potential markers of disease activity in patients with non-systemic JIA (nsJIA) .
Key Dates
- Start date
- Jul 15, 2025
- Status verified
- Jun 2025
- Primary completion
- Apr 15, 2026
- Completion
- Apr 15, 2026
Study Design
- Enrollment
- 90 participants (estimated)
Arms
- Arm: casecases under 16y established diagnosis juvenile idiopathic arthritis
- Arm: controlbelow age 16 y not diagnosed with any autoimmune or systemic disease
Primary Outcome Measure
possibility to use crp to albumin level as novel biomarker to predict disease activity in juvenile 0idiopathic arthritis [ Time Frame: 6 months ]
Central Contacts
- Hadeer F Mohamed, resident01030536331
- osama S Daifallah, AssistantProf
Related Studies
- Development of a Therapeutic Endpoint in Pediatric Rheumatologic ConditionsRecruiting · Children's National Research Institute · Washington D.C., District of Columbia
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.PHASE3 · Recruiting · AbbVie · Phoenix, Arizona
- Pain in Juvenile ArthritisRecruiting · Washington University School of Medicine · St Louis, Missouri